Skip to main content

Table 2 # of subjects in each population positive for both anti-HERV K10 Gag & Pol antibodies

From: Increased seroreactivity to HERV-K10 peptides in patients with HTLV myelopathy

Population N # positive (%)
VBD* 100 0(0)
LGLL* 53 0(0)
HTLVt* 74 18(24)
HTLVm*+ 16 14(88)
HTLVn*+ 58 4(7)
MS*+ 83 4(5)
  1. *p = 1.000, < 0.001, < 0.001, 0.017 and 0.041 for VBD vs LGLL, HTLVt, HTLVm; HTLVn; and MS, respectively.
  2. +p = < 0.001 for HTLVm vs HTLVn or vs MS.